NRSN vs. CTMX, VHAQ, CNTX, QNCX, KRON, UNCY, ONCY, IOBT, OPTN, and RVPH
Should you be buying NeuroSense Therapeutics stock or one of its competitors? The main competitors of NeuroSense Therapeutics include CytomX Therapeutics (CTMX), Viveon Health Acquisition (VHAQ), Context Therapeutics (CNTX), Quince Therapeutics (QNCX), Kronos Bio (KRON), Unicycive Therapeutics (UNCY), Oncolytics Biotech (ONCY), IO Biotech (IOBT), OptiNose (OPTN), and Reviva Pharmaceuticals (RVPH). These companies are all part of the "pharmaceutical products" industry.
NeuroSense Therapeutics vs.
CytomX Therapeutics (NASDAQ:CTMX) and NeuroSense Therapeutics (NASDAQ:NRSN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, community ranking, risk, media sentiment, profitability and institutional ownership.
CytomX Therapeutics has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500. Comparatively, NeuroSense Therapeutics has a beta of 1.27, indicating that its share price is 27% more volatile than the S&P 500.
CytomX Therapeutics received 370 more outperform votes than NeuroSense Therapeutics when rated by MarketBeat users. However, 66.67% of users gave NeuroSense Therapeutics an outperform vote while only 65.38% of users gave CytomX Therapeutics an outperform vote.
CytomX Therapeutics presently has a consensus price target of $5.77, suggesting a potential upside of 640.06%. Given CytomX Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe CytomX Therapeutics is more favorable than NeuroSense Therapeutics.
CytomX Therapeutics has higher revenue and earnings than NeuroSense Therapeutics. NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.
CytomX Therapeutics has a net margin of 10.96% compared to NeuroSense Therapeutics' net margin of 0.00%. NeuroSense Therapeutics' return on equity of 0.00% beat CytomX Therapeutics' return on equity.
In the previous week, CytomX Therapeutics and CytomX Therapeutics both had 1 articles in the media. NeuroSense Therapeutics' average media sentiment score of 1.62 beat CytomX Therapeutics' score of 1.11 indicating that NeuroSense Therapeutics is being referred to more favorably in the news media.
67.8% of CytomX Therapeutics shares are held by institutional investors. Comparatively, 1.0% of NeuroSense Therapeutics shares are held by institutional investors. 7.0% of CytomX Therapeutics shares are held by insiders. Comparatively, 27.4% of NeuroSense Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
CytomX Therapeutics beats NeuroSense Therapeutics on 11 of the 16 factors compared between the two stocks.
Get NeuroSense Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NRSN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NeuroSense Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:NRSN) was last updated on 2/22/2025 by MarketBeat.com Staff
Free NRSN Stock Alerts